Form D · Biotechnology
Quellis Biosciences, Inc.
Waltham, MA · CIK 0001741691
Offering snapshot reported Dec 28, 2020 · SEC filing
- Reported sold
- $0 Offering amount: $1.02M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 14, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 28, 2020 | Initial | $0 | No comparison | 1 | SEC filing |
| Aug 18, 2020 | Amendment | $12,068,212 | $9,568,212vs Dec 11, 2018 | 3 | SEC filing |
| Dec 11, 2018 | Initial | $2,500,000 | No comparison | 1 | SEC filing |
| Jun 1, 2018 | Initial | $0 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Option to acquire
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-384402
Source: Form D, filed Dec 28, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Fred Callori | Director |
| Frederick Callori | Director |
| Chris Garabedian | Director |
| Christopher Garabedian | Director |
| Peter Harwin | Director, Executive |
| Tomas Kiselak | Director, Executive |
| Jonathan Violin | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
203 Crescent Street Bldg. #17, Suite #102 B
Waltham, MA, 02453
Waltham, MA, 02453